A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study

McParland, Penny; Kenyon, Sara; Bae, Sang Cheol; Taylor, D. J.

doi:10.1111/j.1471-0528.2006.01005.x

BJOG

2006

DOI: 10.1111/j.1471-0528.2006.01005.x

|View full text |Cite

A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study

Penny McParland

Sara Kenyon

Sang Cheol Bae

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2006

2018

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We do not believe that there are sufficient grounds to treat women with BV until more evidence is available and agree with McParland et al 1 about the need for further investigation. If clinicians do feel compelled to treat BV (e.g.…”

mentioning

confidence: 52%

See 1 more Smart Citation

Author’s reply: A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study

Shennan¹,

Simcox²,

Briley³

et al. 2006

BJOG

View full text Add to dashboard Cite

A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study Author's ReplySir, We would like to thank McParland et al. 1 for their interest in our article. We agree that fetal fibronectin is not a reliable test for the presence of bacterial vaginosis (BV), nor did we intend it to be. It is, however, efficacious as a predictor of preterm birth, much more so than the rather weaker association between BV and preterm birth. It is not known whether fetal fibronectin positive status reflects the consequences of intrauterine infection, but it is likely that infection will result in a positive test as both are related to delivery. Our conclusion of metronidazole therapy not reducing the incidence of preterm birth refers to those women identified as being high risk from their obstetric history and positive fibronectin status and not from their vaginal flora status.Metronidazole had no influence on the prevalence of BV in our study population (although the number of women with BV was small); however, we would still advise caution

show abstract

mentioning

confidence: 52%

“…We would like to thank McParland et al 1 for their interest in our article. We agree that fetal fibronectin is not a reliable test for the presence of bacterial vaginosis (BV), nor did we intend it to be.…”

mentioning

confidence: 96%

Author’s reply: A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study

Shennan¹,

Simcox²,

Briley³

et al. 2006

BJOG

View full text Add to dashboard Cite

show abstract

The fetal fibronectin test: 25 years after its development, what is the evidence regarding its clinical utility? A systematic review and meta-analysis

Faron

Balepa

Parra

et al. 2018

The Journal of Maternal-Fetal & Neonatal Medicine

View full text Add to dashboard Cite

The fetal fibronectin test should not be used as a screening test for asymptomatic women. For high-risk asymptomatic women, and especially for women with multiple pregnancies, the performance of the fetal fibronectin test was also too low to be clinically relevant. Consensual use as a diagnostic tool for women with suspected preterm labor, the best use policy probably still depends on local contingencies, future cost-effectiveness analysis, and comparison with other more recent available biochemical markers.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study

Cited by 2 publications

References 5 publications

Author’s reply: A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study

Author’s reply: A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study

The fetal fibronectin test: 25 years after its development, what is the evidence regarding its clinical utility? A systematic review and meta-analysis

Contact Info

Product

Resources

About